TY - JOUR
T1 - Hepatitis E virus seroprevalence in three hyperendemic areas
T2 - Nepal, Bangladesh and southwest France
AU - Izopet, Jacques
AU - Labrique, Alain B.
AU - Basnyat, Buddha
AU - Dalton, Harry R.
AU - Kmush, Brittany
AU - Heaney, Christopher D.
AU - Nelson, Kenrad E.
AU - Ahmed, Zabed B.
AU - Zaman, K.
AU - Mansuy, Jean Michel
AU - Bendall, Richard
AU - Sauné, Karine
AU - Kamar, Nassim
AU - Arjyal, Amit
AU - Karkey, Abhilasha
AU - Dongol, Sabina
AU - Prajapati, Krishna Govind
AU - Adhikary, Dinesh
N1 - Funding Information:
The specimen in Bangladesh were collected under an R01 grant AI51/31/2004 from the National Institutes of Health (NIH). Specimen collection in Nepal was supported by the Wellcome Trust of Great Britain. Blood collection in Southwest France was supported by INSERM U1043. We would also like to thank Xiamen University and Wantai Diagnostics for providing the anti-HEV IgG assays used in this analysis. The funders did not play a role in the study design or analysis.
Publisher Copyright:
© 2015.
PY - 2015/9/1
Y1 - 2015/9/1
N2 - Background: Hepatitis E causes a significant burden of disease in developing countries and has recently been increasingly recognized in developed countries. Comparing population anti-hepatitis E virus (HEV) seroprevalence across populations has been difficult. Objectives: The aim of this study was to compare the anti-HEV IgG seroprevalence in both adults and children in three hyper-endemic areas (Nepal, Bangladesh and southwest France) using a sensitive, commercial anti-HEV IgG assay. Study Design: Serum or plasma from adults and children in Nepal (n=498), Bangladesh (. n=. 1,009) and Southwest France (. n=. 1031) were tested for anti-HEV IgG using the Wantai assay. Results: After age-standardization, anti-HEV IgG seroprevalence was 47.1%, 49.8% and 34.0% in Nepal, Bangladesh and southwest France, respectively. There was no difference in seroprevalence by gender in any of the countries. A paucity of infections in children 1-10 years-old was consistently observed (less than 15%) at all 3 locations. Conclusions: Surprisingly similar high rates of anti-HEV antibodies were detected using a common, sensitive assay. Despite differences in the epidemiology and circulating genotype of HEV in Nepal, Bangladesh and southwest France, this study found more similarities in population seroprevalence than expected.
AB - Background: Hepatitis E causes a significant burden of disease in developing countries and has recently been increasingly recognized in developed countries. Comparing population anti-hepatitis E virus (HEV) seroprevalence across populations has been difficult. Objectives: The aim of this study was to compare the anti-HEV IgG seroprevalence in both adults and children in three hyper-endemic areas (Nepal, Bangladesh and southwest France) using a sensitive, commercial anti-HEV IgG assay. Study Design: Serum or plasma from adults and children in Nepal (n=498), Bangladesh (. n=. 1,009) and Southwest France (. n=. 1031) were tested for anti-HEV IgG using the Wantai assay. Results: After age-standardization, anti-HEV IgG seroprevalence was 47.1%, 49.8% and 34.0% in Nepal, Bangladesh and southwest France, respectively. There was no difference in seroprevalence by gender in any of the countries. A paucity of infections in children 1-10 years-old was consistently observed (less than 15%) at all 3 locations. Conclusions: Surprisingly similar high rates of anti-HEV antibodies were detected using a common, sensitive assay. Despite differences in the epidemiology and circulating genotype of HEV in Nepal, Bangladesh and southwest France, this study found more similarities in population seroprevalence than expected.
KW - Adult
KW - Child
KW - Hepatitis E Virus
KW - Seroepidemiologic studies
UR - http://www.scopus.com/inward/record.url?scp=84939620279&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84939620279&partnerID=8YFLogxK
U2 - 10.1016/j.jcv.2015.06.103
DO - 10.1016/j.jcv.2015.06.103
M3 - Article
C2 - 26305817
AN - SCOPUS:84939620279
SN - 1386-6532
VL - 70
SP - 39
EP - 42
JO - Journal of Clinical Virology
JF - Journal of Clinical Virology
ER -